Erica L. Monaco
Known title: Chief Executive OfficerCIK: 0001886200
Associated companies
Transaction History
| BFRI | ▲ Buy | Option Exercise | 76,336 | — | 5/18/2023 | View on chart |
| BFRI | ▲ Buy | Option Exercise | 56,689 | — | 7/1/2022 | View on chart |
| BFRI | ▲ Buy | Option Exercise | 76,336 | — | 5/18/2023 | View on chart |
| BFRI | ▲ Buy | Option Exercise | 56,689 | — | 7/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Biofrontera Q2 2026 Earnings Call Discusses Results
Biofrontera held its Q2 2026 earnings conference call, where management discussed the quarter's results and future plans. The call was broadcast on Benzinga and provided updates on revenue, expenses, and guidance. The stock is trading near the lower end of its 52‑week range and close to the $1.05 support level, which may influence short‑term market reactions.
Biofrontera Q2 2026 Earnings Call Discusses Results. Biofrontera held its Q2 2026 earnings conference call, where management discussed the quarter's results and future plans. The call was broadcast on Benzinga and provided updates on revenue, expenses, and guidance. The stock is trading near the lower end of its 52‑week range and close to the $1.05 support level, which may influence short‑term market reactions.